Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States.
Elizabeth A. Pomfret,Kenneth Washburn,Christoph Wald,Michael A. Nalesnik,David D. Douglas,Mark W. Russo,John P. Roberts,David J. Reich,Myron Schwartz,Luis Mieles,Fred T. Lee,Sander Florman,Francis Y. Yao,Ann M. Harper,Erick B. Edwards,Richard B. Freeman,John R. Lake +16 more
Reads0
Chats0
TLDR
A national conference was held to better characterize the long‐term outcomes of liver transplantation for patients with hepatocellular carcinoma (HCC) and to assess whether it is justified to continue the policy of assigning increased priority for candidates with early‐stage HCC on the transplant waiting list in the United States.About:
This article is published in Liver Transplantation.The article was published on 2010-03-01 and is currently open access. It has received 353 citations till now. The article focuses on the topics: Liver transplantation & Transplant Waiting List.read more
Citations
More filters
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Josep M. Llovet,Michel Ducreux,Riccardo Lencioni,Adrian M. Di Bisceglie,Jean-Francois J. DuFour,Tim F. Greten,Eric Raymond,Tania Roskams,Vincenzo Mazzaferro,Jordi Bruix,Massimo Colombo,Andrew X. Zhu +11 more
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
Journal ArticleDOI
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata,Ann-Lii Cheng,Norihiro Kokudo,Masatoshi Kudo,Jeong Min Lee,Jidong Jia,Ryosuke Tateishi,Kwang Hyub Han,Yoghesh K. Chawla,Shuichiro Shiina,Wasim Jafri,Diana A. Payawal,Takamasa Ohki,Sadahisa Ogasawara,Pei-Jer Chen,Cosmas Rinaldi Adithya Lesmana,Laurentius A. Lesmana,Rino Alvani Gani,Shuntaro Obi,A. Kadir Dokmeci,Shiv Kumar Sarin +20 more
TL;DR: The latest guidelines for the treatment of HCC recommend evidence-based management and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.
Journal ArticleDOI
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.
TL;DR: Studies now aim to identify molecular markers and imaging techniques that can detect patients with HCC at earlier stages and better predict their survival time and response to treatment.
References
More filters
Journal ArticleDOI
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
Vincenzo Mazzaferro,Enrico Regalia,Roberto Doci,Salvatore Andreola,A. Pulvirenti,Federico Bozzetti,F. Montalto,Mario Ammatuna,Alberto Morabito,Leandro Gennari +9 more
TL;DR: Liver transplantation is an effective treatment for small, unresectable hepatocellular carcinomas in patients with cirrhosis and after four years, the actuarial survival rate was 75 percent and the rate of recurrence-free survival was 83 percent.
Journal ArticleDOI
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
Josep M. Llovet,Jordi Bruix +1 more
TL;DR: Chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment and only low‐quality scale trials suggested 1‐year improvement in survival.
Journal ArticleDOI
Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.
Journal ArticleDOI
Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival
Francis Y. Yao,Linda D. Ferrell,Nathan M. Bass,Jessica J. Watson,Peter Bacchetti,Alan P. Venook,Nancy L. Ascher,John P. Roberts +7 more
TL;DR: The current criteria for OLT based on tumor size may be modestly expanded while still preserving excellent survival after OLT, and only pT4 stage and total tumor diameter remained statistically significant in multivariate analysis.
Journal ArticleDOI
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
TL;DR: In conclusion, a proper selection of candidates for resection promotes better results than transplantation, in which the results are significantly hampered by the growing incidence of drop‐outs because of the increasing waiting time.
Related Papers (5)
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzaferro,Josep M. Llovet,Rosalba Miceli,Sherrie Bhoori,M. Schiavo,Luigi Mariani,Tiziana Camerini,Sasan Roayaie,Myron Schwartz,Gian Luca Grazi,René Adam,Peter Neuhaus,Mauro Salizzoni,Jordi Bruix,Alejandro Forner,Luciano De Carlis,Umberto Cillo,Andrew K. Burroughs,Roberto Troisi,Massimo Rossi,Giorgio Enrico Gerunda,Jan Lerut,Jacques Belghiti,Ilka de Fátima Santana Ferreira Boin,Jean Gugenheim,Fedja Rochling,Bart van Hoek,Pietro Majno +27 more